Drug intelligence / Profile preview

NF-GQDs

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems

Overview

NF-GQDs (Non-functionalized Graphene Quantum Dots) are a type of graphene nanoparticle being investigated for their potential in enhancing chemotherapy for glioblastoma multiforme, an aggressive brain cancer. These nanoparticles have demonstrated high biocompatibility and the ability to cross the blood-brain barrier. Their mechanism of action involves altering cell membrane permeability, which facilitates the uptake of chemotherapeutic agents, such as doxorubicin, into cancer cells (U87 human glioblastoma cells) without significantly affecting cortical neurons. This synergistic effect aims to increase the efficacy of chemotherapy while potentially reducing the required drug dose and associated side effects.

Other names: Non-functionalized GQDs

Beyond the preview

Go deeper on NF-GQDs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NF-GQDs.

Explore the full profile